Report Store | Pharma intelligence
  • My Account
    • 0Shopping Cart
  • $0.00
  • Disease analysis
    • Anemias
    • Bacterial infections
    • Bleeding disorders
    • Brain Cancer
    • Breast and gynecological cancer
    • Cardiovascular and Metabolic
    • Central Nervous System
    • Cerebrovascular diseases
    • Dermatology
    • Diabetes and diabetic complications
    • Gastroenterology
    • Gastrointestinal cancer
    • Head and Neck Cancer
    • Hypertension
    • Immunology and Inflammation
    • Infectious Diseases
    • Ischemic heart disease
    • Leukemia
    • Lung Cancer
    • Lymphoma
    • Oncology overview
    • Market Spotlight
    • Mens Health
    • Neurology
    • Oncology
    • Ophthalmology
    • Other Hematological Cancers
    • Other metabolic diseases
    • Other Solid Cancers
    • Pain
    • Psychiatry
    • Respiratory
    • Rheumatology
    • Skin cancer
    • Thrombosis
    • Urological cancer
    • Vaccines
    • Viral infections
    • Women’s Health
  • Strategy analysis
    • Bleeding disorders
    • Breast and gynecological cancer
    • Cardiovascular and Metabolic
    • Central Nervous System
    • Commercial Strategy
    • Dealmaking and R&D
    • Head and Neck Cancer
    • Hot Topics
    • Infectious Diseases
    • KOL Insight
    • Leukemia
    • Lung Cancer
    • Manufacturing
    • Market Access
    • Neurology
    • Oncology
    • Outsourcing
    • Pricing & Reimbursement
    • R&D
    • Regulatory & Therapeutic Area
    • Trends
    • Urological cancer
  • Company analysis
    • Big Pharma
    • Emerging Pharma
    • Hot Topics
    • Japan Pharma
    • M&A Analysis
    • Mid Pharma
  • Drug analysis
    • A
    • B-C
    • D-F
    • G-L
    • M-O
    • P-R
    • S-T
    • U-Z
  • MedTech analysis
    • Allergy
    • Autoimmune / Immunology
    • Cardiovascular
    • Dermatology
    • Endocrine
    • ENT / Dental
    • Gastroenterology
    • Hearing
    • Hematology
    • Infectious Diseases
    • Metabolic
    • Neurology
    • Obstetrics / Gynecology
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Osteoporosis
    • Psychiatry
    • Renal
    • Respiratory
    • Rheumatology
    • Urology
  • Opinion & analysis
    • Business Development
    • Business Management
    • Clinical Trials
    • Digital Health
    • Cybersecurity
    • Compliance & Risk
    • Digital patient management
    • Digital policy & regulation
    • Finance & Pricing
    • Healthcare Innovation
    • ICT and Health
    • Leadership
    • Legislation Regulation & Policy
    • Market Access
    • Market Intelligence
    • Medical
    • Pharmaceutical Device
    • Pharmaceutical Research
    • Strategy & Innovation
    • Tech companies & Data
    • Tech & Pharma
  • Blogs
  • Search
  • Menu
You are here: Home > Disease analysis

Disease analysis


  • Sort by Random
    • Default
    • Custom
    • Name
    • Price
    • Date
    • Popularity (sales)
    • Average rating
    • Relevance
    • Random
    • Product ID
  • Display 15 Products per page
    • 15 Products per page
    • 30 Products per page
    • 45 Products per page
  • Disease Analysis: Schizophrenia

    Read More

    The current dynamics of the antipsychotic market show domination by atypical antipsychotics, mainly oral agents, but there is also increasing uptake of long-acting injectable (LAI) neuroleptics, which will continue. Oral atypical antipsychotics that were historical blockbusters are now facing intense generic erosion. The highest-selling oral antipsychotic is Latuda, one of the newer atypical drugs, but its market exclusivity is only set to last until 2023.

    March 30, 2022
    Find out more
  • epilepsy

    Disease Analysis: Epilepsy

    Read More

    Epilepsy is characterized by recurrent, unprovoked seizures, and is one of the most common chronic neurological disorders globally. A seizure is a transient manifestation of signs and/or symptoms, including a disturbance of consciousness, emotion, behavior, or motor function, which occurs because of abnormal excessive or synchronous neuronal activity in the brain.

    May 6, 2022
    Find out more
  • Drug Delivery: Inhalation Devices

    $4,750.00

    This comprehensive market and medical technology report provides an overview of the inhalation-based devices used in the management of asthma and chronic obstructive pulmonary disease (COPD), and includes an in-depth, product-specific market analysis. Countries covered by this report comprise the US, the five major EU markets (France, Germany, Italy, Spain, and the UK), and Japan.

    October 7, 2019
    Find out more
  • Rheumatoid Arthritis KOL Interview – New Jersey, US

    $599.00

    A US-based key opinion leader provides insights into prescribing habits, the most pressing unmet needs in the market, the role of biosimilars, key marketed brands, and late-phase pipeline therapies for rheumatoid arthritis, including upadacitinib and filgotinib.

    July 31, 2019
    Find out more
  • Disease Analysis: Anemia in Chronic Kidney Disease

    Read More

    Anemia in chronic kidney disease (CKD), defined as a reduction in red blood cells (RBCs) or hemoglobin levels, often results from decreased levels of erythropoietin and increased levels of hepcidin. Erythropoietin is primarily produced in the kidneys and increases the production of RBCs by acting on precursor cells. H

    June 7, 2022
    Find out more
  • Market Spotlight: Attention Deficit Hyperactivity Disorder (ADHD)​

    $1,318.00

    This Market Spotlight report covers the Attention Deficit Hyperactivity Disorder (ADHD)​ market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming and regulatory events, probability of success, licensing and asset acquisition deals, a 10-year disease prevalence forecast, as well as presenting drug-specific revenue forecasts.

    May 26, 2022
    Find out more
  • Market Spotlight: Huntington’s Disease

    $1,318.00

    This Market Spotlight report covers the Huntington’s Disease market, comprising key marketed and pipeline drugs, clinical trials, upcoming events, recent events and analyst opinion, probability of success, licensing and asset acquisition deals, and a 10-year disease prevalence forecast, as well as presenting drug-specific revenue forecasts.

    July 19, 2022
    Find out more
  • Disease Analysis: Chronic Obstructive Pulmonary Disease (COPD)

    Read More

    The “ABCD” GOLD treatment guidelines focus on exacerbation risk and patient-reported outcomes to determine pharmacological treatment strategies, independent of spirometric value. Dual bronchodilator combinations are being considered as the new gold standard over long-acting muscarinic antagonist Spiriva in the treatment of more severe COPD.

    June 15, 2022
    Find out more
  • Disease Analysis: Psoriasis

    Read More

    First-line treatment of milder forms of psoriasis will continue to be with cheaper, topical medications. Use of more expensive, systemic therapies will continue to be relegated to more severe psoriasis.

    June 27, 2022
    Find out more
  • Rheumatoid Arthritis KOL Interview – California, US

    $599.00

    A US-based key opinion leader provides insights into prescribing habits, the most pressing unmet needs in the market, the role of biosimilars, key marketed brands, and late-phase pipeline therapies for rheumatoid arthritis, including upadacitinib and filgotinib.

    July 31, 2019
    Find out more
  • Market Spotlight: Cutaneous T-Cell Lymphoma (CTCL)

    $1,318.00

    This Market Spotlight report covers the Cutaneous T-Cell Lymphoma (CTCL) market, comprising key marketed and pipeline drugs, clinical trials, upcoming and regulatory events, recent events and analyst opinion, probability of success, a 10-year disease incidence and prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.

    May 25, 2022
    Find out more
  • Diabetes Management: Insulin Pumps Market (2019)

    $4,750.00

    This report provides an overview of diabetes, automated insulin pump systems, and a comprehensive market and competitive analysis.

    September 30, 2019
    Find out more
  • Market Spotlight: Norovirus

    $1,318.00

    This Market Spotlight report covers the Norovirus market, comprising key pipeline drugs, clinical trials, probability of success, licensing and asset acquisition deals, and an epidemiological overview.

    July 19, 2022
    Find out more
  • Disease Analysis: Bipolar Disorder

    Read More

    BD is a multifactorial psychiatric mood disorder influenced by social, environmental, and genetic risk factors underlying its etiology. The disorder is characterized by fluctuating mood states, such as mania and depression, interspersed with periods of wellbeing over days and weeks. BD describes a range of disease subtypes, including BD type I, BD type II, and cyclothymia.

    January 19, 2022
    Find out more
  • glaucoma

    Market Spotlight: Glaucoma

    $1,318.00

    This Market Spotlight report covers the Glaucoma market, comprising key pipeline and marketed drugs, clinical trials, upcoming and regulatory events, patent information, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.

    July 18, 2022
    Find out more
Page 10 of 12
Page 10 of 12«‹89101112›»
  • Home
  • Terms and Conditions
  • Refund policy
  • Privacy Policy
  • Cookie Policy
  • Contact Us
  • About Us
  • Discounts
  • Market Spotlight – Reports
  • twitter
  • linkedin
  • Sitemap
Copyright © 2022 Pharma Intelligence UK Limited Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London, SW1P 1WG. Pharma Intelligence UK Limited is part of the Pharma Intelligence Group.

Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!

Pharma Intelligence
This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.
Call Back
Scroll to top